Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

Lester S Borden1, Peter E Clark, M Craig Hall

  • 1Department of Urology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

Current Opinion in Oncology
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

European urology·2026
Same author

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

BJUI compass·2026
Same author

Protocol-driven same day discharge for robotic radical prostatectomy.

Urologic oncology·2025
Same author

Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort.

Urologic oncology·2024
Same author

Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.

Scientific reports·2024
Same author

Reply by Authors.

Urology practice·2024
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Bladder cancer affects millions globally, causing over 130,000 deaths yearly. Developing reliable diagnostic and prognostic markers is crucial for effective bladder cancer treatment selection.

Area of Science:

  • Oncology
  • Urology
  • Molecular Biology

Background:

  • Bladder cancer represents a major global health challenge, with substantial annual mortality and a high prevalence, particularly in the United States.
  • Despite advancements in understanding the molecular and genetic underpinnings of bladder cancer, significant unmet needs persist in clinical practice.
  • Current therapeutic strategies require refinement, especially for high-risk superficial, invasive, and metastatic bladder cancer cases.

Purpose of the Study:

  • To highlight the critical need for novel biomarkers in bladder cancer management.
  • To emphasize the importance of markers for accurate diagnosis, prognosis, and personalized therapy selection.
  • To outline future research directions for improving bladder cancer treatment efficacy.

Main Methods:

Related Experiment Videos

  • Review of current understanding of bladder cancer molecular and genetic events.
  • Analysis of existing therapeutic approaches for different stages of bladder cancer.
  • Identification of gaps in diagnostic and prognostic marker development.

Main Results:

  • Significant progress in molecular and genetic understanding of bladder cancer.
  • Persistent need for reliable clinical markers for diagnosis, prognosis, and treatment selection.
  • Ongoing research is essential for refining treatment strategies across all bladder cancer stages.

Conclusions:

  • Development of reliable bladder cancer biomarkers is paramount for clinical utility.
  • Future research should focus on refining treatments for high-risk and metastatic disease.
  • Personalized therapeutic selection based on molecular markers holds promise for improved patient outcomes.